The global non-small cell lung cancer therapeutics market size is growing impressively due to recent surge in adoption of targeted therapy for treating non-small cell lung cancer. According to a report published by Fortune Business Insights, titled ‘Non-Small Cell Lung Cancer Therapeutics: Global Market Analysis, Insights and Forecasts, 2019-2026,’ the market value will rise substantially from US$ 16,011.7 Mn in 2018 to US$ 43,713.1 Mn by 2026. Fortune Business Insights has further predicted the market to exhibit an impressive CAGR of 13.4% between 2019 and 2026 due to exceptional advancements in targeted therapy in recent years. Such high growth can be attributable to the increasing demand for chemotherapy and targeted therapy. Furthermore, advantages of targeted therapy over other alternatives are in plenty. Driven by this, the demand for targeted therapy for diagnosis will increase, which in turn spurs growth in the global non-small cell lung cancer therapeutics market.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/non-small-cell-lung-cancer-therapeutics-market-100484
Leading Players operating in the Non-Small Cell Lung Cancer Therapeutics Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Genentech (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca
- Pfizer Inc.
- Sanofi
- Novartis AG
- Astellas
- Bristol Myers Squibb
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Millennium Pharmaceuticals, Inc.
- Merck Sharp & Dohme Corp.
The report covers:
- Global Non-Small Cell Lung Cancer Therapeutics Market trends, with detailed analysis on consumer trends & manufacturer trends.
- Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
- Key areas of investments identifying market opportunities and challenges in forecast timeframe.
- Competitive analysis of the industry players along with the overview on strategic management.
- Comprehensive company profiles of the major industry players.
Incorporation of Biological Therapies in Non-Small Cell Lung Cancer Therapeutics to Enable Growth
In recent years, the demand for efficient diagnosis method to treat non-small lung cancer is rising at a fast pace. Clinical studies indicated that biological therapies have massively reduced mortality rate of those affected with non-small cell lung cancer. The development of novel biological therapies has been hugely beneficial in treating non-small cell lung cancer (NSCLC). Biological therapies have had a positive impact on the molecular subsets of various lung cancer categories. NSCLC treatments have been blessed with various advancements in biological therapy concepts and they are now playing a major part in minimizing symptoms of non-small cell lung cancer as well. Thus, the use of biological therapies had a positive impact on the global NSCLC therapeutics market and is likely to favour growth of this market in the forecast period.
Adenocarcinoma to Emerge as The Leading Segment
According to cancer.org, adenocarcinoma accounted for 40% of all lung cancers. Although prevalence of adenocarcinoma is high, it is the least deadly among all types of lung cancers. Adenocarcinoma allows for easy NSCLC prognosis as it can be detected at a very early stage. Furthermore, adenocarcinoma can be treated easily as they spread at a slower rate than other NSCLCs. High chances of diagnosis of adenocarcinoma is a major factor why adenocarcinoma will emerge as the leading segment in the forecast period, as well.
Some of the leading companies that are operating in the global non-small cell lung cancer therapeutics market are Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Novartis AG, Astellas, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. (Takeda), Merck Sharp & Dohme Corp. and others.
Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/non-small-cell-lung-cancer-therapeutics-market-100484
Report Focus:
- Extensive product offerings
- Customer research services
- Robust research methodology
- Comprehensive reports
- Latest technological developments
- Value chain analysis
- Potential Non-Small Cell Lung Cancer Therapeutics Market opportunities
- Growth dynamics
- Quality assurance
- Post-sales support
- Regular report updates
Reasons to Purchase this Report:
- Comprehensive analysis of the Non-Small Cell Lung Cancer Therapeutics Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
